Q: I just received the following email from my daughter whose friend has just been admitted to the hospital and diagnosed with multiple blood clots …
Read moreCategory: Targeted Research
AFib Patients without Cardiovascular Comorbidities do not Have Increased Risk of Stroke. Maybe Anticoagulants are not Warranted in This Group?
BACKGROUND: Atrial fibrillation (AF) is associated with a 5‐fold increased stroke risk. While most patients with AF warrant anticoagulation, optimal treatment remains uncertain for patients …
Read moreCompared to Monotherapy of Newer Antiplatelets, Aspirin is More Cost Effective and Likely Non-Inferior
BACKGROUND: Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y 12 inhibitor versus aspirin for secondary prevention. METHODS: In …
Read moreProduct Q & A From Our Major Sponsor
Q: We have a patient who has been taking Boluoke®. He is having a surgical procedure and has been instructed to stop their prescription of blood …
Read moreApixaban may be Safer than Rivaroxaban in Treating Non-Valvular AFib Patients
BACKGROUND: There is no direct evidence comparing the 2 most commonly prescribed direct oral anticoagulants, apixaban and rivaroxaban, used for stroke prevention in nonvalvular atrial …
Read moreAdding Vasodilatory Prostaglandin E1 Improves Treatment Efficacy of Sudden Sensorineural Hearing Loss
PERSPECTIVES: To evaluate the treatment outcome of vasodilator prostaglandin E1 (PGE1) in treating sudden sensorineural hearing loss (SSNHL) and to determine its effects on platelet …
Read moreProduct Q & A From Our Major Sponsor
Q: A customer of ours has Lyme Disease and is interested in taking Boluoke®. However, she is a Lewis ABH Non-secretor so her immune system …
Read moreValue of CHA2DS2-VASc Score for Prediction and Ruling Out of Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention
BACKGROUND: Acute stent thrombosis is an important complication of stent implantation. The CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke, vascular …
Read moreRole of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations
BACKGROUND: Coronary artery disease and peripheral arterial disease are strong predictors of risk for a future ischemic event. Despite the utilization of effective secondary prevention …
Read more